Zelen design clinical trials: why, when, and how.

Area of Science:

• Clinical Trials Methodology
• Public Health Research
• Health Services Research

Background:

• Introduced in 1979 by Marvin Zelen, this design randomizes treatment assignment before obtaining participant consent.
• The core innovation involves informing participants of their assigned treatment post-randomization and then seeking consent.

Purpose of the Study:

• To review recent applications of Zelen design trials in clinical and public health interventions.
• To explore the suitability and practical considerations of Zelen designs for real-world research.

Main Methods:

• Narrative review of contemporary Zelen design trials.
• Analysis of how Zelen designs address challenges like incomplete adherence and participant motivation.
• Examination of data collection strategies, including reliance on existing records.

Main Results:

• Zelen designs are effective for evaluating real-world intervention effects, particularly with incomplete adherence or varying participant motivation.
• Trials often utilize existing records for participant identification and outcome assessment, necessitating a waiver of pre-randomization informed consent.
• The Revised Common Rule provides criteria for waiving consent, often met by low-risk interventions added to usual care.

Conclusions:

• Zelen design trials are valuable for assessing strategies that promote treatment uptake and for answering pragmatic or policy-related questions.
• These trials are less suitable for efficacy or explanatory research but excel at evaluating real-world consequences.